BW 246C
(Synonyms: 8-epi BW 245C) 目录号 : GC14859
The less active C-8 diastereomer of BW 245C
Cas No.:65705-83-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BW 246C is a DP receptor agonist.
The prostaglandin D2 (PGD2) receptors, members of G protein-coupled receptors, bind and are activated by prostaglandin D2. PGD2 receptors include the following proteins prostaglandin D2 receptor 1 (DP1) and prostaglandin D2 receptor 2 (DP2).
In vitro: BW 246C was found to be the less active C-8 diastereomer of the DP receptor agonist its analog BW 245C, having 70-fold less activity than that of BW 245C. For BW 245C, a significant species variation was observed in the anti-aggregatory potency so that it was about one hundred times more effective than in the human in the rat. However, the relative potencies of PGI2 and PGE1 were found to be similar in both species. Moreove, it was observed that in radioligand binding studies BW 245C had a high affinity and selectivity for PGD2 platelet receptors, and the binding to PGI2 or PGE2 receptors was not found [1].
In vivo: Animal study showed that, an intravenous bolus injection of 250 μg/kg BW 245C to spontaneously hypertensive rats was able to lower both systolic (-23%) and diastolic (-34%) blood pressure [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Town, M. H.,Casals-Stenzel, J. and Schillinger, E. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins 25, 13-28 (1983).
| Cas No. | 65705-83-1 | SDF | |
| 别名 | 8-epi BW 245C | ||
| 化学名 | (4R)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid | ||
| Canonical SMILES | [H]N(C(N(CCC(O)C1CCCCC1)[C@@H]2CCCCCCC(O)=O)=O)C2=O | ||
| 分子式 | C19H32N2O5 | 分子量 | 368.5 |
| 溶解度 | ≤50mg/ml in ethanol;50mg/ml in DMSO;50mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7137 mL | 13.5685 mL | 27.137 mL |
| 5 mM | 0.5427 mL | 2.7137 mL | 5.4274 mL |
| 10 mM | 0.2714 mL | 1.3569 mL | 2.7137 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet